Lifecore Biomedical (LFCR) Stock Price
Lifecore Biomedical Price
Revenue at Lifecore Biomedical has contracted by 2.5% per year over the past 19 years to 129.46 M USD. Earnings per share have declined at 6.4% per year over the last 17 years. Lifecore Biomedical's net margin stands at -23.8%, up from -52.4% several years earlier. Analysts set a median price target of 8.93 USD, implying 84.4% above the current price. Of 11 analysts, 7 rate the stock a buy — an overall Buy consensus. The stock trades about 32% above its 52-week low.
Lifecore Biomedical stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Lifecore Biomedical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Lifecore Biomedical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Lifecore Biomedical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Lifecore Biomedical Price |
|---|---|
| 8/6/2026 | 4.84 USD |
| 8/5/2026 | 4.38 USD |
| 8/4/2026 | 4.41 USD |
| 8/3/2026 | 4.39 USD |
| 7/31/2026 | 4.42 USD |
| 7/30/2026 | 4.36 USD |
| 7/29/2026 | 4.26 USD |
| 7/27/2026 | 4.34 USD |
| 7/23/2026 | 4.43 USD |
| 7/22/2026 | 4.58 USD |
| 7/21/2026 | 4.64 USD |
| 7/20/2026 | 4.69 USD |
| 7/17/2026 | 4.68 USD |
| 7/16/2026 | 4.95 USD |
| 7/15/2026 | 4.86 USD |
| 7/14/2026 | 4.61 USD |
| 7/13/2026 | 4.78 USD |
| 7/10/2026 | 4.75 USD |
| 7/9/2026 | 4.75 USD |
| 7/8/2026 | 4.64 USD |
| 7/7/2026 | 4.86 USD |
| 7/6/2026 | 5.07 USD |
| 7/2/2026 | 5.09 USD |
| 7/1/2026 | 5.27 USD |
| 6/30/2026 | 5.25 USD |
| 6/29/2026 | 4.96 USD |
| 6/26/2026 | 5.17 USD |
| 6/25/2026 | 5.39 USD |
| 6/24/2026 | 5.80 USD |
| 6/23/2026 | 5.66 USD |
| 6/22/2026 | 5.52 USD |
| 6/18/2026 | 5.54 USD |
| 6/17/2026 | 5.52 USD |
| 6/16/2026 | 5.35 USD |
| 6/15/2026 | 5.49 USD |
| 6/12/2026 | 5.64 USD |
| 6/11/2026 | 5.65 USD |
| 6/10/2026 | 5.65 USD |
| 6/9/2026 | 5.66 USD |
| 6/8/2026 | 5.57 USD |
| 6/5/2026 | 5.63 USD |
| 6/4/2026 | 5.79 USD |
| 6/3/2026 | 5.67 USD |
| 6/2/2026 | 5.45 USD |
| 6/1/2026 | 4.85 USD |
| 5/29/2026 | 5.02 USD |
| 5/28/2026 | 4.97 USD |
| 5/27/2026 | 4.82 USD |
| 5/26/2026 | 4.80 USD |
| 5/22/2026 | 4.93 USD |
| 5/21/2026 | 4.98 USD |
| 5/20/2026 | 4.57 USD |
| 5/19/2026 | 4.38 USD |
| 5/18/2026 | 4.38 USD |
| 5/15/2026 | 4.40 USD |
| 5/14/2026 | 4.55 USD |
| 5/13/2026 | 4.50 USD |
| 5/12/2026 | 4.56 USD |
| 5/11/2026 | 4.50 USD |
| 5/8/2026 | 4.79 USD |
| 5/7/2026 | 4.77 USD |
| 5/6/2026 | 4.96 USD |
| 5/5/2026 | 5.16 USD |
| 5/4/2026 | 5.13 USD |
| 5/1/2026 | 5.26 USD |
| 4/30/2026 | 5.07 USD |
| 4/29/2026 | 4.94 USD |
| 4/28/2026 | 5.12 USD |
| 4/27/2026 | 5.08 USD |
| 4/24/2026 | 5.02 USD |
| 4/23/2026 | 5.03 USD |
| 4/22/2026 | 5.23 USD |
| 4/21/2026 | 5.23 USD |
| 4/20/2026 | 5.35 USD |
| 4/17/2026 | 5.38 USD |
| 4/16/2026 | 5.20 USD |
| 4/15/2026 | 5.38 USD |
| 4/14/2026 | 5.20 USD |
| 4/13/2026 | 4.94 USD |
| 4/10/2026 | 4.75 USD |
| 4/9/2026 | 4.72 USD |
| 4/8/2026 | 4.24 USD |
| 4/7/2026 | 4.11 USD |
| 4/6/2026 | 4.07 USD |
| 4/2/2026 | 3.84 USD |
| 4/1/2026 | 3.84 USD |
| 3/31/2026 | 3.72 USD |
| 3/30/2026 | 3.79 USD |
| 3/27/2026 | 3.66 USD |
| 3/26/2026 | 3.87 USD |
| 3/25/2026 | 4.19 USD |
| 3/24/2026 | 4.00 USD |
| 3/23/2026 | 4.05 USD |
| 3/20/2026 | 4.02 USD |
| 3/19/2026 | 4.06 USD |
| 3/18/2026 | 4.15 USD |
| 3/17/2026 | 4.36 USD |
| 3/16/2026 | 4.37 USD |
| 3/13/2026 | 6.54 USD |
| 3/12/2026 | 6.61 USD |
| 3/11/2026 | 6.81 USD |
| 3/10/2026 | 6.90 USD |
| 3/9/2026 | 6.98 USD |
| 3/6/2026 | 6.96 USD |
| 3/5/2026 | 7.02 USD |
| 3/4/2026 | 7.06 USD |
| 3/3/2026 | 6.99 USD |
| 3/2/2026 | 7.23 USD |
| 2/27/2026 | 7.20 USD |
| 2/26/2026 | 7.37 USD |
| 2/25/2026 | 7.33 USD |
| 2/24/2026 | 7.22 USD |
| 2/23/2026 | 7.29 USD |
| 2/20/2026 | 7.13 USD |
| 2/19/2026 | 7.20 USD |
| 2/18/2026 | 7.26 USD |
| 2/17/2026 | 7.16 USD |
| 2/13/2026 | 7.08 USD |
| 2/12/2026 | 7.00 USD |
| 2/11/2026 | 7.23 USD |
| 2/10/2026 | 7.38 USD |
| 2/9/2026 | 7.46 USD |
| 2/6/2026 | 7.57 USD |
| 2/5/2026 | 7.56 USD |
| 2/4/2026 | 7.90 USD |
| 2/3/2026 | 7.97 USD |
| 2/2/2026 | 8.52 USD |
| 1/30/2026 | 8.69 USD |
| 1/29/2026 | 8.51 USD |
| 1/28/2026 | 8.56 USD |
| 1/27/2026 | 8.67 USD |
| 1/26/2026 | 8.82 USD |
| 1/23/2026 | 8.58 USD |
| 1/22/2026 | 8.59 USD |
| 1/21/2026 | 8.43 USD |
| 1/20/2026 | 8.25 USD |
| 1/16/2026 | 8.22 USD |
| 1/15/2026 | 8.10 USD |
| 1/14/2026 | 7.88 USD |
| 1/13/2026 | 7.46 USD |
| 1/12/2026 | 7.59 USD |
| 1/9/2026 | 7.56 USD |
| 1/8/2026 | 7.77 USD |
| 1/7/2026 | 7.89 USD |
| 1/6/2026 | 7.91 USD |
| 1/5/2026 | 7.80 USD |
| 1/2/2026 | 7.74 USD |
| 12/31/2025 | 8.18 USD |
| 12/30/2025 | 8.09 USD |
| 12/29/2025 | 8.25 USD |
| 12/26/2025 | 8.30 USD |
| 12/24/2025 | 8.25 USD |
| 12/23/2025 | 8.06 USD |
| 12/22/2025 | 8.17 USD |
| 12/19/2025 | 8.04 USD |
| 12/18/2025 | 8.42 USD |
| 12/17/2025 | 8.47 USD |
| 12/16/2025 | 7.71 USD |
| 12/15/2025 | 7.88 USD |
| 12/12/2025 | 7.79 USD |
| 12/11/2025 | 7.81 USD |
| 12/10/2025 | 7.63 USD |
| 12/9/2025 | 7.59 USD |
| 12/8/2025 | 7.51 USD |
| 12/5/2025 | 7.63 USD |
| 12/4/2025 | 7.77 USD |
| 12/3/2025 | 7.64 USD |
| 12/2/2025 | 7.72 USD |
| 12/1/2025 | 7.82 USD |
| 11/28/2025 | 7.90 USD |
| 11/26/2025 | 7.83 USD |
| 11/25/2025 | 7.90 USD |
| 11/24/2025 | 7.51 USD |
| 11/21/2025 | 7.64 USD |
| 11/20/2025 | 7.37 USD |
| 11/19/2025 | 7.49 USD |
| 11/18/2025 | 7.60 USD |
| 11/17/2025 | 7.90 USD |
| 11/14/2025 | 7.96 USD |
| 11/13/2025 | 7.89 USD |
| 11/12/2025 | 8.22 USD |
| 11/11/2025 | 7.74 USD |
| 11/10/2025 | 7.29 USD |
| 11/7/2025 | 6.85 USD |
| 11/6/2025 | 6.62 USD |
| 11/5/2025 | 6.77 USD |
| 11/4/2025 | 6.78 USD |
| 11/3/2025 | 7.11 USD |
| 10/31/2025 | 7.19 USD |
| 10/30/2025 | 7.10 USD |
| 10/29/2025 | 7.06 USD |
| 10/28/2025 | 6.90 USD |
| 10/27/2025 | 6.73 USD |
| 10/24/2025 | 6.78 USD |
| 10/23/2025 | 6.81 USD |
| 10/22/2025 | 6.74 USD |
| 10/21/2025 | 6.76 USD |
| 10/20/2025 | 6.63 USD |
| 10/17/2025 | 6.49 USD |
| 10/16/2025 | 6.53 USD |
| 10/15/2025 | 6.69 USD |
| 10/14/2025 | 6.54 USD |
| 10/13/2025 | 6.61 USD |
| 10/10/2025 | 6.50 USD |
| 10/9/2025 | 6.63 USD |
| 10/8/2025 | 6.87 USD |
| 10/7/2025 | 6.74 USD |
| 10/6/2025 | 6.85 USD |
| 10/3/2025 | 6.98 USD |
| 10/2/2025 | 7.06 USD |
| 10/1/2025 | 7.17 USD |
| 9/30/2025 | 7.36 USD |
| 9/29/2025 | 7.15 USD |
| 9/26/2025 | 7.01 USD |
| 9/25/2025 | 6.81 USD |
| 9/24/2025 | 7.06 USD |
| 9/23/2025 | 7.90 USD |
| 9/22/2025 | 7.88 USD |
| 9/19/2025 | 7.87 USD |
| 9/18/2025 | 7.93 USD |
| 9/17/2025 | 7.70 USD |
| 9/16/2025 | 7.86 USD |
| 9/15/2025 | 7.68 USD |
| 9/12/2025 | 7.52 USD |
| 9/11/2025 | 7.77 USD |
| 9/10/2025 | 7.01 USD |
| 9/9/2025 | 7.26 USD |
| 9/8/2025 | 7.29 USD |
| 9/5/2025 | 7.53 USD |
| 9/4/2025 | 7.94 USD |
| 9/3/2025 | 7.71 USD |
| 9/2/2025 | 7.46 USD |
| 8/29/2025 | 7.61 USD |
| 8/28/2025 | 7.62 USD |
| 8/27/2025 | 7.53 USD |
| 8/26/2025 | 7.50 USD |
| 8/25/2025 | 7.59 USD |
| 8/22/2025 | 7.60 USD |
| 8/21/2025 | 7.22 USD |
| 8/20/2025 | 7.24 USD |
| 8/19/2025 | 7.25 USD |
| 8/18/2025 | 7.40 USD |
| 8/15/2025 | 7.37 USD |
| 8/14/2025 | 7.42 USD |
| 8/13/2025 | 7.74 USD |
| 8/12/2025 | 7.63 USD |
| 8/11/2025 | 7.22 USD |
| 8/8/2025 | 7.24 USD |
Lifecore Biomedical Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Lifecore Biomedical Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 539.00 | 541.00 | 532.00 | 524.00 | 557.00 | 160.00 | 100.00 | 185.00 | 111.00 | 128.00 | 128.00 | 129.00 | 122.00 | 130.00 | 150.00 | 182.00 |
| 13.24 | 0.37 | -1.66 | -1.50 | 6.30 | -71.27 | -37.50 | 85.00 | -40.00 | 15.32 | – | 0.78 | -5.43 | 6.56 | 15.38 | 21.33 |
| 12.06 | 12.94 | 15.60 | 14.89 | 14.54 | 24.38 | 38.00 | 27.03 | 35.14 | 32.03 | 31.25 | 31.01 | 31.01 | 31.01 | 31.01 | 31.01 |
| 65.00 | 70.00 | 83.00 | 78.00 | 81.00 | 39.00 | 38.00 | 50.00 | 39.00 | 41.00 | 40.00 | 40.00 | 37.83 | 40.31 | 46.51 | 56.43 |
| 18.00 | -19.00 | 15.00 | 11.00 | 8.00 | -25.00 | -8.00 | -34.00 | -5.00 | 27.00 | -16.00 | -1.00 | -10.00 | -10.00 | -12.00 | -15.00 |
| 3.34 | -3.51 | 2.82 | 2.10 | 1.44 | -15.63 | -8.00 | -18.38 | -4.50 | 21.09 | -12.50 | -0.78 | -8.20 | -7.69 | -8.00 | -8.24 |
| 13.00 | -11.00 | 10.00 | 24.00 | 2.00 | -38.00 | -32.00 | -97.00 | -116.00 | 12.00 | -38.00 | -30.00 | -36.00 | -34.00 | -41.00 | -22.00 |
| -31.58 | -184.62 | -190.91 | 140.00 | -91.67 | -2,000.00 | -15.79 | 203.13 | 19.59 | -110.34 | -416.67 | -21.05 | 20.00 | -5.56 | 20.59 | -46.34 |
| 27.42 | 27.62 | 27.88 | 27.79 | 29.16 | 29.28 | 29.47 | 30.30 | 30.46 | 34.36 | 37.40 | 37.48 | 37.48 | 37.48 | 37.48 | 37.48 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Lifecore Biomedical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Lifecore Biomedical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Lifecore Biomedical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Lifecore Biomedical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Lifecore Biomedical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Lifecore Biomedical stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Lifecore Biomedical Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Lifecore Biomedical business model & stock analysis
Lifecore Biomedical SWOT Analysis
Strengths
1. Strong market presence and well-established brand reputation.
2. Diversified product portfolio across different industries.
3. Robust research and development capabilities, leading to innovative and high-quality products.
Weaknesses
1. Reliance on a few major customers, making the company vulnerable to their changing demands or loss of contracts.
2. Limited geographic presence, mainly operating within specific regions.
3. Higher production costs compared to some competitors.
Opportunities
1. Growing demand for environmentally friendly products, providing an opportunity for the company's sustainable packaging solutions.
2. Expansion into new markets and industries, leveraging existing expertise and capabilities.
3. Acquisition or partnership opportunities to enhance product offerings or access new distribution channels.
Threats
1. Intense competition from both established players and new entrants in the industry.
2. Economic downturns or fluctuations in the market affecting consumer spending patterns.
3. Increasing regulations and compliance requirements impacting product development and manufacturing processes.
Lifecore Biomedical Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Lifecore Biomedical Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Lifecore Biomedical historical P/E ratio, EBIT multiple, and P/S ratio
Lifecore Biomedical annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Lifecore Biomedical shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Lifecore Biomedical forecasts and price targets in August 2026
Analyst Price Targets 2026Lifecore Biomedical Analyst Rating Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| 6/16/2026 | Maintained | Outperform | |
| 4/29/2026 | Maintained | Outperform | |
| 3/27/2026 | Maintained | Outperform | |
| 3/24/2026 | Maintained | Outperform | |
| 3/17/2026 | Upgrade | Market PerformOutperform | |
| 1/3/2025 | Maintained | Equal Weight | |
| 11/22/2024 | Maintained | Buy | |
| 8/28/2024 | Downgrade | OutperformMarket Perform | |
| 9/1/2023 | Maintained | Equal Weight | |
| 9/1/2023 | Maintained | Outperform |
Lifecore Biomedical Earnings Calls
Lifecore Biomedical Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 4/8/2026 | -0.22USD | - | 31.96 MUSD | - | 2026 Q3 |
| 12/31/2025 | -0.19USD | - | 32.99 MUSD | - | 2026 Q2 |
| 5/30/2024 | 0.06USD | - | 34.80 MUSD | - | 2024 Q3 |
| 10/4/2023 | -0.23USD | - | 25.04 MUSD | - | 2024 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Lifecore Biomedical stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Lifecore Biomedical shareholder structure
| % | Name |
|---|---|
13.50765% | |
12.72821% | |
10.61157% | |
6.21061% | |
5.45678% | |
4.94608% |
Lifecore Biomedical Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
17.10% | SEC ↗ | |
17.10% | SEC ↗ | |
16.90% | SEC ↗ | |
16.60% | SEC ↗ | |
16.60% | SEC ↗ | |
15.60% | SEC ↗ | |
9.80% | SEC ↗ | |
7.89% | SEC ↗ | |
7.89% | SEC ↗ | |
6.74% | SEC ↗ |
Lifecore Biomedical Executives and Management Board
12 members · avg. age 59 · 17 % women
Mr. Ryan Lake (47)
Chief Financial Officer
4.16 M USD
Management
Mr. Thomas Salus (56)
Chief Legal and Administrative Officer , Secretary
Mr. Paul Josephs (60)
President, Chief Executive Officer, Director · since 2024
Ms. Stephanie Diaz
Investor Relations · since 2024
Board of Directors
Ms. Katrina Houde (67)
Independent Chairman of the Board
Mr. Joshua Schechter (52)
Independent Director
Mr. Nelson Obus (78)
Independent Director
Mr. Paul Johnson (67)
Independent Director
Mr. Christopher Kiper (54)
Independent Director
Mr. Humberto Antunes (64)
Independent Director
Frequently asked questions about Lifecore Biomedical
The business model of Landec Corp revolves around developing and commercializing innovative health and wellness solutions. Landec Corp primarily focuses on creating and selling differentiated products through two business segments: Curation Foods and Lifecore Biomedical. Curation Foods offers a wide range of plant-based foods, such as fresh packaged salads, vegetables, and fruit snacks, while Lifecore Biomedical specializes in developing and manufacturing various biomaterials and products for medical applications. With a commitment to sustainability and healthy living, Landec Corp aims to provide customers with high-quality, environmentally friendly products that enhance overall well-being.
Landec Corp is primarily active in the food packaging and biomaterial industries.
The main competitors of Landec Corp in the market include companies such as Archer-Daniels-Midland Company, Cargill Incorporated, and Ingredion Incorporated.
Landec Corp is a renowned company with a rich history and background. Founded in 1986, Landec Corp has grown to become a leading lifesciences company specializing in innovative health and wellness solutions. With headquarters in Menlo Park, California, Landec Corp focuses on the development and commercialization of differentiated products in various industries. The company is dedicated to solving challenges in agriculture, food, and biomedical materials through its proprietary technologies. Landec Corp has built a strong reputation for delivering high-quality, sustainable products, and its commitment to innovation has propelled its growth and success in the market.
Landec Corp has achieved several significant milestones throughout its history. One notable milestone was the acquisition of Lifecore Biomedical in 2013, which expanded their presence in the healthcare industry. Another important achievement was the introduction of the patented BreatheWay technology, which extended the shelf life of fresh produce. In addition, Landec Corp has successfully established strategic partnerships with major retailers, such as Walmart and Whole Foods, further enhancing their market reach. These accomplishments have solidified Landec Corp's position as a leading player in the technology-driven food and biomedical markets.
Landec Corp is primarily present in the United States.
Landec Corp represents a set of core values and a corporate philosophy focused on innovation, sustainability, and growth. The company prioritizes delivering innovative solutions and products that address the evolving needs of its customers. Landec Corp aims to contribute positively to the environment and society by employing sustainable practices across its operations. It actively invests in research and development to stay at the forefront of technology advancements, fostering growth opportunities. Through its commitment to operational excellence and customer satisfaction, Landec Corp strives to establish itself as a trusted leader in its industry.
Analysts currently set an average price target of 8.93 USD for the Lifecore Biomedical stock (median: 8.93 USD), implying +84.4 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Lifecore Biomedical stock: 7 recommend buying, 4 holding and 0 selling.
Converted at the current exchange rate, the Lifecore Biomedical share trades at 4.19 EUR (4.84 USD).
The Lifecore Biomedical share (LFCR) is listed on 2 stock exchanges, including: NASDAQ (LNDC), Frankfurt (LDE.F).
Landec Corporation is a company specialized in the development and marketing of innovative and sustainable products in various areas. Its main divisions are Lifecore Biomedical and Curation Foods. Lifecore Biomedical produces medical devices and technologies for the field of regenerative medicine, such as implants, artificial joints, and other medical instruments. These products are developed and manufactured in collaboration with medical professionals, using advanced materials and technologies. On the other hand, Curation Foods operates in the food industry, offering different types of fruits and vegetables produced in a healthy and sustainable way. Some of Landec Corp's products include "Eat Smart" products from Curation Foods, which offer various vegetable and fruit salads as well as ready-to-eat meals. The company combines sustainable agriculture, modern processing methods, and innovative packaging design. Another product is IntelliBond, a special micronutrient additive for animal feed. Through patented technology, IntelliBond is designed to be better absorbed by animals, effectively preventing nutrient deficiencies. Landec Corp's business model aims to develop and market sustainable products that improve the health of people and animals while preserving the environment. The company emphasizes close collaboration between scientists, technology experts, and other professionals to develop innovative solutions tailored to the needs of customers and consumers. In addition, the company strives to integrate sustainability principles into its production and supply chains to reduce environmental impacts and conserve resources. This includes the use of recyclable materials and the promotion of projects to improve agriculture and environmental protection. Overall, Landec Corp offers a wide range of innovative and sustainable products in various sectors, focusing on the needs of customers and consumers. The company values sustainability, quality, and innovation, and relies on close collaboration among professionals from different fields to develop sustainable solutions.
The revenue of Lifecore Biomedical is 129.46 M USD. This figure is based on current financial data and reflects the company's business performance.
The profit of Lifecore Biomedical is -30.79 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Lifecore Biomedical is currently -5.89. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lifecore Biomedical stock.
The price-to-sales ratio (P/S) of Lifecore Biomedical is currently 1.40. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lifecore Biomedical stock.
The Eulerpool Quality Score for Lifecore Biomedical is 2/10.
The ISIN of Lifecore Biomedical is US5147661046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Lifecore Biomedical is 899376. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Lifecore Biomedical is LFCR. The ticker symbol is used to trade Lifecore Biomedical shares on the stock exchange.
Lifecore Biomedical paid dividends every year for the past 0 years.
Lifecore Biomedical is assigned to the 'Non-cyclical consumption' sector.
The dividends of Lifecore Biomedical are distributed in USD.
Lifecore Biomedical stock
Lifecore Biomedical Peer Group
Lifecore Biomedical Ticker
Lifecore Biomedical FIGI
All fundamentals and in-depth analysis of Lifecore Biomedical
Our stock analysis for Lifecore Biomedical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lifecore Biomedical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.